OUOleg Ursu

Oleg Ursu

*This is an algorithmically generated author record based on publicly available information.

Oleg Ursu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PepSeA: Peptide Sequence Alignment and Visualization Tools to Enable Lead Optimization

    by Javier L. Baylon, Oleg Ursu, Anja Muzdalo, Anne Mai Wassermann, Gregory L. Adams, Martin Spale, Petr Mejzlik, Anna Gromek, Viktor Pisarenko, Dzianis Hancharyk, et al.

    Therapeutic peptides offer potential advantages over small molecules in terms of selectivity, affinity, and their ability to target "undruggable" proteins that are associated with a wide range of pathologies. Despite their importance, current molecular design capabilities that inform medicinal chemistry decisions on peptide programs are limited. More specifically, there are unmet needs for structure-activity relationship (SAR) analysis and visualization of linear, cyclic, and cross-linked peptides containing non-natural motifs, which are widely used in drug discovery. To bridge this gap, we developed PepSeA (Peptide Sequence Alignment and Visualization), an open-source, freely available package of sequence-based tools (https://github.com/Merck/PepSeA). PepSeA enables multiple sequence alignment of non-natural amino acids and enhanced visualization with the hierarchical editing language for macromolecules (HELM). Via stepwise SAR analysis of a ChEMBL peptide data set, we demonstrate the utility of PepSeA to accelerate decision making in lead optimization campaigns in pharmaceutical setting. PepSeA represents an initial attempt to expand cheminformatics capabilities for therapeutic peptides and to enable rapid and more efficient design-make-test cycles.


  • Open Access

    Machine learning prediction and tau-based screening identifies potential Alzheimer’s disease genes relevant to immunity

    by Jessica Binder, Oleg Ursu, Cristian Bologa, Shanya Jiang, Nicole Maphis, Somayeh Dadras, Devon Chisholm, Jason Weick, Orrin Myers, Praveen Kumar, et al.

    With increased research funding for Alzheimer’s disease (AD) and related disorders across the globe, large amounts of data are being generated. Several studies employed machine learning methods to understand the ever-growing omics data to enhance early diagnosis, map complex disease networks, or uncover potential drug targets. We describe results based on a Target Central Resource Database protein knowledge graph and evidence paths transformed into vectors by metapath matching. We extracted features between specific genes and diseases, then trained and optimized our model using XGBoost, termed MPxgb(AD). To determine our MPxgb(AD) prediction performance, we examined the top twenty predicted genes through an experimental screening pipeline. Our analysis identified potential AD risk genes: FRRS1, CTRAM, SCGB3A1, FAM92B/CIBAR2, and TMEFF2. FRRS1 and FAM92B are considered dark genes, while CTRAM, SCGB3A1, and TMEFF2 are connected to TREM2-TYROBP, IL-1β-TNFα, and MTOR-APP AD-risk nodes, suggesting relevance to the pathogenesis of AD.


  • Open Access

    PepSeA: Peptide Sequence Alignment and Visualization Tools to Enable Lead Optimization

    by Javier L. Baylon, Oleg Ursu, Anja Muzdalo, Anne Mai Wassermann, Gregory L Adams, Martin Spale, Petr Mejzlik, Anna Gromek, Viktor Pisarenko, Dzianis Hancharyk, et al.

    Therapeutic peptides offer potential advantages over small molecules in terms of selectivity, affinity, and their ability to target “undruggable” proteins that are associated with a wide range of pathologies. Despite their importance, there are currently no adequate molecular design capabilities that inform medicinal chemistry decisions on peptide programs. More specifically, SAR (Structure-Activity Relationship) analysis and visualization of linear, cyclic, and cross-linked peptides containing non-natural motifs, which are widely used in drug discovery. To bridge this gap, we developed PepSeA ( Pep tide Se quence A lignment and Visualization), an open-source, freely available package of sequence-based tools ( https://github.com/Merck/PepSeA ). PepSeA enables multi-sequence alignment of non-natural amino acids and enhanced HELM (Hierarchical Editing Language for Macromolecules) visualization. Via stepwise SAR analysis of a ChEMBL peptide dataset, we demonstrate PepSeA’s power to accelerate decision making in lead optimization campaigns in pharmaceutical settings. PepSeA represents an initial attempt to expand cheminformatics capabilities for therapeutic peptides and to enable rapid and more efficient design–make–test cycles.

  • Learning reference-enriched approach towards large scale active ontology alignment and integration

    by Qiong Cheng, Oleg Ursu, Tudor I. Oprea, Stephan Schurer

    With the increasing number of ontologies being designed to represent and manage knowledge in all sorts of sectors, ontology alignment and integration become more and more important in aggregating intelligent efforts on homogenous and heterogeneous data. From the computational perspective, it is challenging due to the ubiquitous existence of diverse classifications of same data. In this paper, we propose an active ontology integration and alignment system, which plugs in expandable learning reference context pool. In the reference context pool, we have integrated WordNet, MeSH, and external curated mapping sources (ICD9 to SNOMEDCT) with an extension to injecting UMLS. The active ontology integration and alignment system takes account of not only subsumption tree but also directed acyclic graph underlying ontologies. It allows 1) finding exact one-to-one matching terms of pairwise ontologies, 2) finding inexact one-to-one term mappings, where two terms have at least a concept in common on basis of the lexical context, and 3) finding one-to-many concept mappings, where one concept can be lexically mapped to the combination of multiple exclusive concepts.


  • Protein biomarker druggability profiling

    by Subramani Mani, Daniel Cannon, Robin Ohls, Tudor Oprea, Stephen Mathias, Karri Ballard, Oleg Ursu, Cristian Bologa


  • Open Access

    Chronic obstructive pulmonary disease phenotypes using cluster analysis of electronic medical records

    by Rodrigo Vazquez Guillamet, Oleg Ursu, Gary Iwamoto, Pope L Moseley, Tudor Oprea

    Chronic obstructive pulmonary disease is a heterogeneous disease. In this retrospective study, we hypothesize that it is possible to identify clinically relevant phenotypes by applying clustering methods to electronic medical records. We included all the patients >40 years with a diagnosis of chronic obstructive pulmonary disease admitted to the University of New Mexico Hospital between 1 January 2011 and 1 May 2014. We collected admissions, demographics, comorbidities, severity markers and treatments. A total of 3144 patients met the inclusion criteria: 46 percent were >65 years and 52 percent were males. The median Charlson score was 2 (interquartile range: 1–4) and the most frequent comorbidities were depression (36%), congestive heart failure (25%), obesity (19%), cancer (19%) and mild liver disease (18%). Using the sphere exclusion method, nine clusters were obtained: depression–chronic obstructive pulmonary disease, coronary artery disease–chronic obstructive pulmonary disease, cerebrovascular disease–chronic obstructive pulmonary disease, malignancy–chronic obstructive pulmonary disease, advanced malignancy–chronic obstructive pulmonary disease, diabetes mellitus–chronic kidney disease–chronic obstructive pulmonary disease, young age–few comorbidities–high readmission rates–chronic obstructive pulmonary disease, atopy–chronic obstructive pulmonary disease, and advanced disease–chronic obstructive pulmonary disease. These clusters will need to be validated prospectively.


  • Open Access

    Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen–Fluorogen Activating Protein Binding Pair

    by Yang Wu, Shaun R. Stauffer, Robyn L. Stanfield, Phillip H. Tapia, Oleg Ursu, Gregory W. Fisher, Christopher Szent-Gyorgyi, Annette Evangelisti, Anna Waller, J. Jacob Strouse, et al.